RxDoctor Payments Data

Eric Leichter, MD

Urology · Aberdeen, SDNPI 1295822104

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Astellas Pharma US Inc at 44.9% of the total. That places this record below the midpoint for urology clinicians in SD, where the typical reported total is $713.

$218in general payments, 2019–2025

Across 9 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$98
  • Medtronic$46
  • AbbVie$25
  • Valencia Technologies Corporation$19
  • Merck$17
  • Johnson & Johnson$14

What the payments were for

  • Food & beverage$218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$218 in reported general payments places this provider in the 30th percentile of 40 urology providers in South Dakota.

See all urology providers in South Dakota

Medicare billing

Part B allowed, 2024
$108,926
Medicare patients
417
Services billed
1,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron159$62,896
GemtesaVibegron15$6,856
Potassium Citrate ErPotassium Citrate42$5,631
Trospium Chloride ErTrospium Chloride19$3,662
Darifenacin ErDarifenacin Hydrobromide20$1,600
Tamsulosin Hcl164$1,536
Oxybutynin Chloride ErOxybutynin Chloride59$1,333
Solifenacin Succinate16$660
Finasteride53$497
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$460
Allopurinol38$204
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$190
Cefdinir11$173
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim58$139
Ciprofloxacin Hcl17$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$98$62,896159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 40 urology providers in South Dakota.

Other urology in Aberdeen

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →